NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

Provided By PR Newswire

Last update: Jan 28, 2022

BOSTON, Jan. 28, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022. Mr. Strickland will serve as Chair of the Company's Audit Committee.